This is not just about looking cute in a bikini somewhere, she says
Background GLP-1 agonists continue to strain plan sponsor budgets due to soaring utilization rates
Heres an example of just how long the road ahead is: Stanford tells Endocrine News that she was recently interviewed by a reporter from a large, national publication, who asked her, Youre talking about medications
There were no significant differences in dietary intake based on participants ethnicity, GLP-1RA usage duration, and education
GLP-1 receptor agonist medications work by mimicking this hormone
And as the buzz on these medications, especially semaglutide, grows louder, people are flocking to doctors or the black market to get their hands on them, even people who dont have obesity or diabetes